



SERIES ADJUSTMENT - 2009-201546
ONN INFORMATION CIRCULAR # 201546
March 26, 2009

GENENTECH, INC. (DNA) - Completed Cash Merger

On Wednesday, March 25, 2009, Roche Investments USA completed its full tender offer for Genentech, Inc. (DNA) Common Shares. Pursuant to the terms of the merger, each existing DNA Common Share will be converted into the right to receive \$95.00 net cash per share. **The merger became effective today, Thursday, March 26, 2009.**

Pending Contract Adjustments

Pursuant to the by-laws of The Options Clearing Corporation ("OCC"), all Genentech, Inc. options will be adjusted as follows:

Adjustment Date:	Friday, March 27, 2009
New Deliverable/Contract:	\$9,500.00 (\$95.00 x 100) cash per contract

PLEASE NOTE:

All resting orders for DNA options in the BOX order book will be cancelled by the BOX Market Operations Center after the close on Thursday, March 26, 2009.

Questions regarding this release may be directed to BOX Market Operations Center at 1-617-235-2249 or 1-866-768-8845 Toll Free